Course Content 1

Total Page:16

File Type:pdf, Size:1020Kb

Course Content 1 Course content 1 Chemotherapeutic agents Mechanism of actions Indications Contraindications/Cautions Drug interactions Side-effects/Adverse reactions Dosage regimen (occasionally) Reference Books 2 Pharmacology by Rang, Dale, Ritter, Gardner Clinical Pharmacology textbooks British National Formulary (BNF) 3 Antifungal agents 4 Most fungi are commensals or live in the environment. But increasing incidence and severity of human fungal infections Fungal infections are termed mycoses and in Generally can be divided into: 1) Superficial infections 2) Cutaneous infections 3) Sub-cutaneous infections 4) Systemic infections FUNGAL INFECTIONS 5 blastomycosis candidiasis histoplasmosis mucorymycosis ringworm Factors increasing incidence and severity 6 of human fungal infections Widespread use of broad-spectrum antibiotics (antimicrobial drugs) Reduced immune responses caused by AIDS Use of immunosuppressant drugs Administration of anticancer drugs (cancer chemotherapy) Chronic use of steroids (spreading of an infection) FUNGAL INFECTIONS 7 Fungal infections. are usually more difficult to treat than bacterial infections Fungal organisms grow slowly Fungal infections often occur in tissues that are poorly penetrated by antimicrobial agents Eg: devitalized or avascular tissues ANTIFUNGAL AGENTS 8 The Azoles Griseofulvin Flucytosine The polyenes Echinocandin antifungals (new) 9 I. Antifungals damaging permeability of the cell membrane • Imidazoles: Bifonazole, Clotrimazole, Econazole, Ketoconazole, Miconazole • Triazoles: Fluconazole, Itraconazole, Voriconazole • Allylamines: Terbinafine, Naftifine • Morpholines: Amorolfine • Thiocarbamates: Tolciclate, Tolnaftate • Substituted pyridones: Ciclopirox • Polyene antibiotics: Amphotericin B, Nystatin 10 II. Antifungals inhibiting cell wall synthesis • Echinocandins: Caspofungin, anidulafungin and micafungin III. Antifungals inhibiting synthesis of nucleic acids • Flucytosine • Griseofulvin????? 11 AZOLES 12 Comprise the imidazoles and triazoles 13 Imidazoles: Miconazole Bifonazole Ketoconazole Butoconazole Clotrimazole Econazole Fenticonazole Tioconazole Isoconazole Oxiconazole Sertaconazole Sulconazole Triazoles: Fluconazole Itraconazole Ravuconazole Posaconazole Voriconazole 14 Mechanism of action Azoles inhibit the enzyme cytochrome P450 14α- demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell membrane synthesis Azoles 15 Reduced fungal membrane ergosterol concentrations result in damaged, leaky cell membranes Azoles inhibiting cytochrome P450 enzymes (inhibits biosynthesis of adrenal and gonadal steroid hormones) The toxicity of these drugs depends on their relative affinities for mammalian and fungal cytochrome P450 enzymes. The triazoles tend to have fewer side effects, better absorption, better drug distribution in body tissues, and fewer drug interactions. KETOCONAZOLE 16 Spectrum of activity includes Candida species ٭ Coccidioides immitis ٭ Cryptococcus neoformans ٭ * Dermatophytes & Pityriasis versicolor Pharmacokinetics 17 An acid environment is necessary for ketoconazole absorption Administration of food with ketoconazole appears to increase absorption due possibly to: 1) increased bile secretions 2) delayed gastric emptying Does not cross the intact blood-brain barrier except in meningitis. Urinary concentrations of ketoconazole are usually low, but vaginal and vaginal tissue concentrations correlate with those in serum. KETOCONAZOLE 18 Metabolized through oxidation, dealkylation, aromatic hydroxylation. Excreted into the bile, faeces and the urine Bile Faeces Urine Side effects 19 Impotence Gynaecomastia Reduced sperm count Decreased libido Hepatotoxicity Nausea/vomiting Pruritis Dizziness Photophobia Contraindications/Precautions 20 Achlorhydria Hypochlorhydria Alcoholism Breast-feeding Children Hepatic disease Pregnancy Drug interactions 21 Antacids H2 blockers Omeprazole Isoniazid Corticosteroids Ethanol Phenytoin Rifampicin Astemizole Amphotericin B Miconazole, Econazole, Clotrimazole 22 Bioavailability is low when administered orally Usually used topically. Fluconazole 23 Does not require an acidic environment, as does ketoconazole, for GI absorption. About 80 to 90% absorbed from GIT. Thet1/2 of the drug is 27 to 37 h, permitting once-daily dosing in patients with normal renal function. Only 11% of the circulating drug is bound to plasma proteins. Fluconazole 24 The drug penetrates widely into most body tissues eg CSF therefore effective for treating fungal meningitis. About 80% of the drug is excreted unchanged in the urine. Dosage reductions are required in the presence of renal insufficiency. Alopecia and hepatic necrosis have been reported as adverse effects Itraconazole 25 Lipophilic and water insoluble Requires a low gastric pH for absorption. Oral bioavailability is variable (20 to 60%). It is highly protein bound (99%) Metabolized in the liver and excreted into the bile. Useful in the treatment of disseminated histoplasmosis in AIDS, nonmeningeal blastomycosis and sporotrichosis Itraconazole 26 Contraindicated in conditions of hepatic and renal impairment, pregnancy and breastfeeding mothers Side effects include nausea, abdominal pain and rash. Flatulence, constipation, menstrual disorders and alopecia may occur. GRISEOFULVIN 27 Fermentation product of Penicillium griseofulvum Mode of action not exactly understood but involves nucleic acid synthesis and cell mitosis Dermatophyte infections of the skin, scalp, hair and nails Infections where susceptible strains of Trichophyton, Microsporum and Epidermaphyte are implicated. Griseofulvin also is deposited in keratin cells on the surface of the skin making it difficult for fungus to invade the skin and other tissues Pharmacokinetics 28 Well absorbed after oral administration. Presence of fat in the diet appears increase absorption of griseofulvin Metabolized in the liver and then excreted in urine Drug Interactions 29 Barbiturates ( e.g. Phenobarbitone) Warfarin Oestrogen Progesterone preparations Toxicity and Side Effects 30 Headache Abdominal discomfort Rashes Fatigue, Dizziness (enhance effect of alcohol) Confusion and impaired co-ordination POLYENE ANTIFUNGALS 31 Amphotericin B Mechanism of Action: Destroys the integrity of cellular membrane of susceptible organism by binding to ergosterol Active against most fungi and yeast Treatment of systemic fungal infections. Not absorbed from the gut Given by IV infusion 32 Toxic Effects 33 Anorexia, Nausea, Vomiting, diarrhoea, epigastric pain Headache, Muscle and Joint pain Disturbances in renal and liver functions Neurological and blood disorders Clinical Uses 34 Drug of choice in most systemic mycoses Candidiasis Cryptococcosis Aspergillosis Mucormycosis. Nystatin 35 Produced from Streptomyces noursei Active against Candida albicans infections of skin and mucous membranes Not absorbed when given by mouth Its activity is affected by long exposure to light, and heat Side Effects 36 Nausea Vomiting and Diarrhoea (at high doses) Oral irritation Rashes (topical and vaginal forms) Flucytosine (5-flucytosine, 5-FC) 37 Fluorinated purimidine related to fluouracil and floxuridine An analogue of cytosine that was originally synthesized for possible use as an antineoplastic agent. 5-FC is converted to 5-fluorouracil inside the cell by the fungal enzyme cytosine deaminase. The active metabolite 5-fluorouracil interferes with fungal DNA synthesis by inhibiting thymidylate synthetase. Incorporation of these metabolites into fungal RNA inhibits protein synthesis. Indicated for :Crytococcus neoformans (Crytococcal), Candida infections (UTI’s) and Torulopsis glabrata 38 Pharmacokinetics 39 Rapidly and well absorbed in GI tract Widely distributed in the body Minimally bound to proteins Approximately 80% excreted in the urine (unchanged) Half-life 3-6 hours Side Effects 40 Leukopenia Thrombocytopenia Rash Nausea and vomiting diarrhoea. Severe enterocolitis Confusion, headache, sedation Drug Interactions 41 Amphotericin Cytotoxics Allylamines 42 Reversible noncompetitive inhibitors of the fungal enzyme squalene epoxidase, which converts squalene to lanosterol. These agents exhibit fungicidal activity against dermatophytesand fungistatic activity against yeasts. Naftifine is available for topical use only in the treatment of cutaneous dermatophyte and Candida infections. 43 Terbinafine 44 Dermatophyte infections of the nails and ringworm infections Available for topical and systemic use Lipophilic and highly binds to plasma protiens Cautions Hepatic and renal impairment Pregnancy Breast feeding Drug interactions 45 Rifampicin Cimetidine Famotidine Side effects 46 Abdominal discomfort Anorexia Urticaria rash Taste disturbance Photosensitivity ECHINOCANDIN ANTIFUNGALS 47 Mode of action: inhibit ß-(1,3) glucan synthesis, damaging fungal cell walls no drug target in mammalian cells Rapidly fungicidal against most Candida spp. Fungistatic against Aspergillus spp. Active against cyst form of Pneumocystis carinii. 48 Caspofungin 49 Pharmacokinetics Administration: IV 96% plasma protein bound Predominantly hepatic metabolism (hydrolysis and N-acetylation). Distribution: urinary concentration low, CSF concentration expected to be low Adverse effects 50 Fever Hepatotoxicity raised transaminases common in patients receiving caspofungin hepatic necrosis in animals given large
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul
    USOO6767552B2 (12) United States Patent (10) Patent No.: US 6,767,552 B2 Narang (45) Date of Patent: Jul. 27, 2004 (54) ADHESIVE TREATMENT FOR ORAL 5.530,037 A 6/1996 McDonnell et al. FUNGAL INFECTION 5,554,365 A 9/1996 Byram et al. 5,575.997 A 11/1996 Leung et al. (75) Inventor: Upvan Narang, Raleigh, NC (US) 5,580,565 A 12/1996 Tighe et al. 5,582,834 A 12/1996 Leung et al. (73) Assignee: Closure Medical Corporation, 5,613,942 A 3/1997 Lucast et al. Raleigh, NC (US) 5,624,669 A 4/1997 Leung et al. 9, 5,653,769 A 8/1997 Barley, Jr. et al. 5,661,170 A 8/1997 Chodosh (*) Notice: Subject to any disclaimer, the term of this 5,665,817 A 810: E. al. patent is extended or adjusted under 35 5,684,042 A 11/1997 Greff et al. U.S.C. 154(b) by 359 days. 5,716,607 A 2/1998 Byram et al. 5,717.005 A 2/1998 Richardson (21) Appl. No.: 09/898,092 5,725,491 A 3/1998 Tipton et al. 5,730,994. A 3/1998 Askill et al. (22) Filed: Jul. 5, 2001 5,753,699 A 5/1998 Greff et al. 5,755,680 A 5/1998 Ghodsian (65) Prior Publication Data 5,762.919 A 6/1998 Greff et al. 5,762.955 A 6/1998 Smith US 2003/0007947 A1 Jan. 9, 2003 5,783,177 A 7/1998 Greff et al.
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    1816 1990/826 THE DRUG TARIFF 1990 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS I. Title and commencement 15. Disputes 2. Interpretation PART I PART III GENERAL RULES AFFECTING DIRECTION MISCELLANEOUS PROVISIONS 3. Scope of direction 16. Claims on Department 4. Standards I 7. Allergy treatment sets 5. Charges for requirements 18. Payment for non·disposable syringes and needles PART 11 19. Payment for plastic syringes RULES FOR PRICING 20. Period and quantity of supply for 6. Calculation of payments doctors' and midwives' prescriptions 7. Application of Pricing Schedules 21. Period and quantity of supply for 8. Computation of selling price prescriptions for oral contraceptives 9. Rounding calculations 22. Period and quantity of supply for 10. Minimum charges dentist's prescriptions 11. Adjustment of dose volumes of oral 23. Original packs, and certain antibiotics liquid requirements 24. Bulk supply orders 12. Water 25. Practitioner's supply orders 13. Payment for bulk supply orders 26. Wholesale supply orders 14. Payment for practitioners' supply 27. Revocations and savings orders Schedule DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1990. (2) This direction shall come into force on the 1st day of December 1990. 2. Interpretation-(1) In this direction, unless the context otherwise requires,- "The Act" means the Social Security Act 1964: "Board" means an Area Health Board under the Area Health Boards Act 1983 or a Hospital
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • US5116603.Pdf
    ||||||||||||||||||| US0051 16603A United States Patent (19) 11) Patent Number: 5,116,603 Friedman (45) Date of Patent: May 26, 1992 (54) ORAL ANTIFUNGAL PREVENTATIVE, AND 99.0957 5/1965 United Kingdom . METHOD OF USE OTHER PUBLICATIONS 75 Inventor: Michael Friedman, Jerusalem, Israel Friedman, "Plaque Inhibition by Sustained Release of 73) Assignee: Yissum Research Development Chlorhexide', J. Dental Res. Nov. 1985. Company of the Hebrew University of Soskolne, W. A. et al., "New Sustained Release Dosage Jerusalem, Jerusalem, Israel form of Chlorhexidine for Dental Use', J. Periodontal Res. 18:330-336, (1983). (21) Appl. No.: 465,786 Friedman, "New Sustained Release form of Chlorhexi 22 Filed: Jan. 18, 1990 dine for Denteal Use', J. Periodont Res. 17:323-328 (1982). Related U.S. Application Data Kostiala, I. et al., Acta Odontol. Scand. 37:87-101 (1979). Budtz-Jörgensen, E. et al., Community Dent. Oral 63 Continuation-in-part of Ser. No. 304,092, Jan. 31, 1989, Epidemiol. 3:115 (1975). abandoned. Odds, F. C., CRC Crit Rey. Microbiol. 15: 1-5 (1987). (51 int. Cl. ....................... A61K 6/00; A61K 31/74; Lehner, T. in Clin. Aspects of Immunol, P.G.H. Gell A61K 31/745; A61K 31/78 eds. et al., 3rd edition, Blackwell Scientific Public, Ox 52 U.S. Cl. ........................................ 424/53; 424/49; ford, 1975, pp. 1387-1427. 514/900; 514/902 Friedman, M. et al., IADR Prog. and Abstr. 59:905 58) Field of Search ....................... 424/78, 81, 83, 53, (1980), No. 72. 424/49; 514/900, 902,953 Friedman, M. et al., J. Dent. Res. 64:1319-1321 (1985).
    [Show full text]
  • Anti-Fungal Agent Antimykotischer Wirkstoff Agent Antifongique
    (19) TZZ _¥_T (11) EP 2 762 139 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61P 31/10 (2006.01) 13.04.2016 Bulletin 2016/15 C07D 409/06 (2006.01) (21) Application number: 12836654.9 (86) International application number: PCT/JP2012/074580 (22) Date of filing: 25.09.2012 (87) International publication number: WO 2013/047530 (04.04.2013 Gazette 2013/14) (54) ANTI-FUNGAL AGENT ANTIMYKOTISCHER WIRKSTOFF AGENT ANTIFONGIQUE (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • YASUKO NANJO ET AL.: ’In vitro Antifungal GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Activities of Clinically Available Topical PL PT RO RS SE SI SK SM TR Antifungal Drugs’ JAPANESE JOURNAL OF DERMATOLOGYvol. 117, no. 2, 20 February 2007, (30) Priority: 26.09.2011 JP 2011209903 pages 149 - 152, XP008173701 • NIWANO Y ET AL.: ’Efficacy of NND-502, a novel (43) Date of publication of application: imidazole antimycotic agent, in experimental 06.08.2014 Bulletin 2014/32 models of Candida albicans and Aspergillus fumigatus infections’ INTERNATIONAL (73) Proprietor: Nihon Nohyaku Co., Ltd. JOURNAL OF ANTIMICROBIAL AGENTS vol. 12, Tokyo 104-8386 (JP) no. 3, August 1999, pages 221 - 228, XP055104990 • SHIGERU ABE ET AL.: ’Anti-Candida Activities of (72) Inventors: Azole Antifungals in the Presence of Lysozyme • KOGA, Hiroyasu In Vitro’ JAPANESE JOURNAL OF MEDICAL Kawachinagano-shi MYCOLOGY vol. 39, no.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Review Article Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
    Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 204237, 13 pages http://dx.doi.org/10.1155/2013/204237 Review Article Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents Claudia Spampinato1,2 and Darío Leonardi3,4 1 Departamento de Qu´ımica Biologica,´ Facultad de Ciencias Bioqu´ımicas y Farmaceuticas,´ Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina 2 Centro de Estudios Fotosinteticos´ y Bioqu´ımicos (CEFOBI, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina 3 Departamento de Tecnolog´ıa Farmaceutica,´ Facultad de Ciencias Bioqu´ımicas y Farmaceuticas,´ Universidad Nacional de Rosario (UNR), Suipacha 531, 2000 Rosario, Argentina 4 Instituto de Qu´ımica Rosario (IQUIR, UNR-CONICET), Suipacha 531, 2000 Rosario, Argentina Correspondence should be addressed to Dar´ıo Leonardi; [email protected] Received 8 April 2013; Revised 6 June 2013; Accepted 6 June 2013 Academic Editor: Abdelwahab Omri Copyright © 2013 C. Spampinato and D. Leonardi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive. Superficial infections often affect the skin or mucous membranes and can be treated successfully with topical antifungal drugs. However, invasive fungal infections are often life-threatening, probably due to inefficient diagnostic methods and inappropriate initial antifungal therapies. Here, we briefly review our current knowledge of pathogenic species of the genus Candida and yeast infection causes and then focus on current antifungal drugs and resistance mechanisms.
    [Show full text]
  • Determination of Cost Effective Topical Therapy for Pityriasis Versicolor Fawad Muzaffar*, Amer Ejaz**, Khalid Mahmood†
    Journal of Pakistan Association of Dermatologists 2008; 18: 159-164. Original Article Determination of cost effective topical therapy for pityriasis versicolor Fawad Muzaffar*, Amer Ejaz**, Khalid Mahmood† * Dermatology Department, Combined Military Hospital, Kohat Cantonment, Pakistan. ** Dermatology Department, Combined Military Hospital, Kharian Cantonment, Pakistan. † Dermatology Department, PAF Hospital Islamabad, Pakistan. Abstract Objective To compare the cost, efficacy and compliance between shampoo (2.5 % selenium sulphide), soap (3% salicylic acid-10% sulphur), and gel (2% ketoconazole) in the treatment of pityriasis versicolor. Patients and methods This comparative, randomized, single-blind clinical trial study was carried out at Combined Military Hospital Multan from May 2005 to September 2005. After randomization and assessment of inclusion criteria, patients with diagnosis of pityriasis versicolor were divided into three groups. Group I applied shampoo for 10 minutes daily for 1 week. Group II applied soap for 5 minutes daily for a period of 4 weeks. Group III applied gel for 5 minutes daily for 5 days. Cure was defined as negative skin scrapings for fungal hyphae at the end of treatment period. Cost of treatment was defined as cost of treatment for the group at baseline divided by the number of cured patients in each group at the end of treatment period. Efficacy was defined as the percentage of cure rate achieved at the end of treatment period. Compliance was defined as the number of patients completing treatment in each group. Patients were evaluated at presentation, at the end of treatment, and followed up at 4 weeks post treatment. Results 90 patients were enrolled, 63 patients completed the treatment period, and 44 patients completed the follow up period.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Orally Active Tolciclate and Tolnaftate
    Europaisches Patentamt @ � European Patent Office @ Publication number: 0 063 773 A1 Office europeen des brevets ^ 1 © EUROPEAN PATENT APPLICATION g> Application number: 82103281.0 ® Int. CI.3: A 61 K 31/325 g) Date of filing: 19.04.82 @> Priority: 29.04.81 US 258830 @ Applicant: ADRIA LABORATORIES INC., P.O. Box16529, Columbus Ohio (US) @ Inventor: Imondi, Anthony Rocco, 4515 Ravine Drive, @ Date of publication of application : 03.1 1 .82 Westerville Ohio 43081 (US) Bulletin 82/44 Inventor: Shemano, Irving, 2420 Haviland Road, Columbus Ohio 43220 (US) @ Representative: Wey, Hans-Heinrich, Dipl.-lng. et al, @ Designated Contracting States: AT BE CH DE FR GB IT Patentanwalte Muller-Borner Wey & Korner LI LUNLSE Widenmayerstrasse 49, D-8000 Miinchen 22 (DE) @ Orally active tolciclate and tolnaftate. It has been found that fungal diseases can be effectively treated systemically by oral administration of tolciclate or tolnaffate. The drugs will generally be administered in divided daily doses in the form of tablets, capsules, syrups or suspensions. This invention relates to treating fungal diseases. More particularly, this invention relates to the systemic treatment of fungal diseases by oral administration of an antifungal agent selected from tolciclate and tolnaftate and to medica- ments containing said agents for oral administration. The human body is subject to many fungal infections, some of which have been a problem to man since before recorded his- tory. Modern science has been successful in treating many fungal diseases. The most success has occurred in the topical treatment on exposed areas of the body. Numerous compounds are known to be effective in such topical treatment.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]